433 related articles for article (PubMed ID: 20962266)
41. B lymphocytes and cancer: a love-hate relationship.
Yuen GJ; Demissie E; Pillai S
Trends Cancer; 2016 Dec; 2(12):747-757. PubMed ID: 28626801
[No Abstract] [Full Text] [Related]
42. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
[TBL] [Abstract][Full Text] [Related]
43. Omics-wide quantitative B-cell infiltration analyses identify GPR18 for human cancer prognosis with superiority over CD20.
Liu Y; Wang L; Lo KW; Lui VWY
Commun Biol; 2020 May; 3(1):234. PubMed ID: 32398659
[TBL] [Abstract][Full Text] [Related]
44. Margin-infiltrating CD20(+) B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma.
Shi JY; Gao Q; Wang ZC; Zhou J; Wang XY; Min ZH; Shi YH; Shi GM; Ding ZB; Ke AW; Dai Z; Qiu SJ; Song K; Fan J
Clin Cancer Res; 2013 Nov; 19(21):5994-6005. PubMed ID: 24056784
[TBL] [Abstract][Full Text] [Related]
45. The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3.
Stel AJ; Kroesen BJ; Jacobs S; Groen H; de Leij LF; Kluin-Nelemans HC; Withoff S
J Immunol; 2004 Nov; 173(10):6009-16. PubMed ID: 15528335
[TBL] [Abstract][Full Text] [Related]
46. The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells.
Lepletier A; Lutzky VP; Mittal D; Stannard K; Watkins TS; Ratnatunga CN; Smith C; McGuire HM; Kemp RA; Mukhopadhyay P; Waddell N; Smyth MJ; Dougall WC; Miles JJ
Immunol Cell Biol; 2019 Feb; 97(2):152-164. PubMed ID: 30222899
[TBL] [Abstract][Full Text] [Related]
47. CD20
Sato J; Kitano S; Motoi N; Ino Y; Yamamoto N; Watanabe S; Ohe Y; Hiraoka N
Cancer Sci; 2020 Jun; 111(6):1921-1932. PubMed ID: 32277550
[TBL] [Abstract][Full Text] [Related]
48. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.
Theyer G; Kramer G; Assmann I; Sherwood E; Preinfalk W; Marberger M; Zechner O; Steiner GE
Lab Invest; 1992 Jan; 66(1):96-107. PubMed ID: 1370561
[TBL] [Abstract][Full Text] [Related]
49. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
[TBL] [Abstract][Full Text] [Related]
50. Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome.
Daridon C; Pers JO; Devauchelle V; Martins-Carvalho C; Hutin P; Pennec YL; Saraux A; Youinou P
Arthritis Rheum; 2006 Jul; 54(7):2280-8. PubMed ID: 16802367
[TBL] [Abstract][Full Text] [Related]
51. Regulatory T cells in cancer; can they be controlled?
Adeegbe DO; Nishikawa H
Immunotherapy; 2015; 7(8):843-6. PubMed ID: 26316166
[No Abstract] [Full Text] [Related]
52. The Emerging Role of B Cells in Tumor Immunity.
Tsou P; Katayama H; Ostrin EJ; Hanash SM
Cancer Res; 2016 Oct; 76(19):5597-5601. PubMed ID: 27634765
[TBL] [Abstract][Full Text] [Related]
53. B cells, plasma cells and antibody repertoires in the tumour microenvironment.
Sharonov GV; Serebrovskaya EO; Yuzhakova DV; Britanova OV; Chudakov DM
Nat Rev Immunol; 2020 May; 20(5):294-307. PubMed ID: 31988391
[TBL] [Abstract][Full Text] [Related]
54. [Rethinking the place of B lymphocyte and tertiary lymphoid structures in oncoimmunotherapy].
Germain C; Kaplon H; Dieu-Nosjean MC
Med Sci (Paris); 2021 Feb; 37(2):130-133. PubMed ID: 33591255
[No Abstract] [Full Text] [Related]
55. Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma.
Theurich S; Schlaak M; Steguweit H; Heukamp LC; Wennhold K; Kurschat P; Rabenhorst A; Hartmann K; Schlösser H; Shimabukuro-Vornhagen A; Holtick U; Hallek M; Stadler R; von Bergwelt-Baildon M
J Clin Oncol; 2016 Apr; 34(12):e110-6. PubMed ID: 25348001
[No Abstract] [Full Text] [Related]
56. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
[TBL] [Abstract][Full Text] [Related]
57. T-cell infiltrate after monoclonal anti-CD20 antibody therapy for B-cell lymphoma.
Vincent-Salomon A; Mathiot C; Macintyre E; Girre V; Fourquet A; Mercier C; Fréneaux P; Dumont J; Decaudin D
Leuk Lymphoma; 2000 Apr; 37(3-4):387-91. PubMed ID: 10752990
[No Abstract] [Full Text] [Related]
58. Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity.
Luo CT; Liao W; Dadi S; Toure A; Li MO
Nature; 2016 Jan; 529(7587):532-6. PubMed ID: 26789248
[TBL] [Abstract][Full Text] [Related]
59. Gains and losses of CD8, CD20 and CD56 expression in tumor stroma-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and lymphocytes from tumor draining lymph nodes in serous papillary ovarian carcinoma patients.
Papadopoulos N; Kotini A; Cheva A; Jivannakis T; Manavis J; Alexiadis G; Lambropoulou M; Vavetsis S; Tamiolakis D
Eur J Gynaecol Oncol; 2002; 23(6):533-6. PubMed ID: 12556098
[TBL] [Abstract][Full Text] [Related]
60. Activation of infiltrating cytotoxic T lymphocytes and lymphoma cell apoptotic rates in gastric MALT lymphomas. Differences between high-grade and low-grade cases.
Guidoboni M; Doglioni C; Laurino L; Boiocchi M; Dolcetti R
Am J Pathol; 1999 Sep; 155(3):823-9. PubMed ID: 10487840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
